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ABSTRACT 1 
Background: The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-2 
HF), showed that dapagliflozin, added to other guideline-recommended therapies, reduced the 3 
risk of mortality and heart failure hospitalization, and improved symptoms, in patients with heart 4 
failure and reduced ejection fraction (HFrEF). We examined the effects of dapagliflozin according 5 
to age, given potential concerns about efficacy and safety of therapies in the elderly. 6 
Methods: Patients in New York Heart Association (NYHA) functional class ≥II, with a left ventricular 7 
ejection fraction (LVEF) ≤40%, and a modest elevation of N-terminal pro-B-type natriuretic peptide 8 
(NT-proBNP) were eligible. Key exclusion criteria included systolic blood pressure <95 mmHg and 9 
estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2. The primary outcome was the 10 
composite of an episode of worsening heart failure (HF hospitalization or urgent HF visit) or 11 
cardiovascular (CV) death, whichever occurred first. 12 
Results: 4744 patients aged 22-94 years were randomized (mean age was 66.3 [SD 10.9] years). 13 
636 patients were aged <55 years (13.4%), 1242 aged 55-64 (26.2%), 1717 aged 65-74 (36.2%) and 14 
1149 ≥75 years (24.2%). The rate of the primary outcome (per 100 person years, placebo arm) in 15 
each age group was: 13.6 (95% CI 10.4-17.9), 15.7 (13.2-18.7), 15.1 (13.1-17.5) and 18.0 (15.2-21.4) 16 
with corresponding dapagliflozin/placebo hazard ratios (95% CI): 0.87 (0.60-1.28), 0.71 (0.55-0.93), 17 
0.76 (0.61-0.95), and 0.68 (0.53-0.88), P-interaction=0.76. Consistent benefits were observed for 18 
the components of the primary outcome, all-cause mortality and symptoms.  Although adverse 19 
events and study drug discontinuation increased with age, neither was significantly more common 20 
with dapagliflozin in any age group. 21 
5 
 
Conclusion: Dapagliflozin reduced the risk of death and worsening heart failure, and improved 1 
symptoms, across the broad spectrum of age studied in DAPA-HF. There was no significant 2 
imbalance in tolerability or safety events between dapagliflozin and placebo, even in elderly 3 
individuals. 4 
 5 
Clinical Trial Registration: 6 
URL: https://clinicaltrials.gov/ct2/show/NCT03036124; ClinicalTrials.gov Unique Identifier: 7 
NCT03036124. 8 
  9 
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CLINICAL PERSPECTIVE 1 
 2 
What is new? 3 
• In the placebo-controlled Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure 4 
trial (DAPA-HF), dapagliflozin, added to other guideline-recommended therapies, reduced 5 
the risk of mortality and heart failure hospitalization, and improved symptoms in 4744 6 
patients with heart failure and reduced ejection fraction (HFrEF) 7 
• The effects of dapagliflozin were consistent across the spectrum of age studied (22-94 8 
years), both in terms of efficacy and safety. 9 
 10 
What are the clinical implications? 11 
• The benefit of dapagliflozin is consistent in older as well as younger patients, including in 12 
individuals aged ≥75 years. 13 
• This risk adverse events with dapagliflozin was not greater in older, compared to younger 14 
patients. 15 
• Advanced age per se is not a reason to withhold treatment with dapagliflozin in patients with 16 
HFrEF. 17 
  18 
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INTRODUCTION 1 
As populations in many countries age rapidly, the number of elderly patients with heart failure is 2 
increasing steeply. However, in other regions, such as Latin America, Africa and parts of Asia, 3 
individuals with heart failure are typically younger than those in, for example North America and 4 
Western Europe. [1–4]. It is, therefore, very important to understand the efficacy and safety of new 5 
treatments in all age groups, although tolerability may be a particular concern in the elderly, not just 6 
because of advanced age, but also because of polypharmacy. The benefit of therapy may also be 7 
questioned in the elderly. [5–7].  8 
In the placebo-controlled Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial 9 
(DAPA-HF), dapagliflozin, added to other guideline-recommended therapies, reduced the risk of 10 
mortality and heart failure hospitalization, and improved symptoms in 4744 patients with heart 11 
failure and reduced ejection fraction (HFrEF) [8]. The average age of patients randomized in DAPA-12 
HF was 66 years and 36% of patients were aged 66 to 75 years and 21% were >75 years. We have 13 
examined the efficacy and safety of dapagliflozin according to age in a post hoc analysis of DAPA-HF.  14 
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METHODS 1 
DAPA-HF was a randomized, double-blind, controlled trial in patients with HFrEF, which evaluated the 2 
efficacy and safety of dapagliflozin 10 mg once daily, compared with matching placebo, added to 3 
standard care. The design, baseline characteristics, and primary results of the trial have been 4 
published  [8–10]. The Ethics Committee of each of the 410 participating institutions (in 20 countries) 5 
approved the protocol, and all patients gave written informed consent. The corresponding author had 6 
full access to all of the trial data and takes responsibility for its integrity and the data analysis. The data 7 
that support the findings of this study are available from the corresponding author on reasonable 8 
request. 9 
 10 
Study patients 11 
Men and women aged ≥18 years with HF were eligible if they were in New York Heart Association 12 
(NYHA) functional class ≥II, had a left ventricular ejection fraction (LVEF) ≤40%, and were optimally 13 
treated with pharmacological and device therapy for HF. Participants were also required to have a N-14 
terminal pro-B-type natriuretic peptide (NT-proBNP) concentration ≥600 pg/mL (≥400 pg/mL if 15 
hospitalized for HF within the previous 12 months). Patients with atrial fibrillation or atrial flutter were 16 
required to have a NT-proBNP level ≥900 pg/mL, irrespective of history of HF hospitalization. Key 17 
exclusion criteria included: symptoms of hypotension or systolic blood pressure <95 mmHg, estimated 18 
glomerular filtration rate (eGFR) <30 mL/min/1.73m2 (or rapidly declining renal function), type 1 19 
diabetes mellitus, and another condition likely to prevent patient participation in the trial or greatly 20 
limit life expectancy. A full list of exclusion criteria is provided in the design paper [9]. 21 
 22 
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Study procedures 1 
After the provision of informed consent, visit 1 started a 14-day screening period during which the 2 
trial inclusion and exclusion criteria were checked, and baseline information were collected. Visit 2 3 
was the randomization visit and randomization was stratified based on diagnosis of type 2 diabetes 4 
(defined as an established diagnosis or a glycated haemoglobin level of ≥6.5% [≥48 mmol per mole]) 5 
at screening. After randomization, follow-up visits took place at 14 and 60 days, and then at 120, 240, 6 
360 days and every four months thereafter. The visit early after randomization (14 days) was included 7 
to check renal function and blood pressure (as well as for symptoms of hypotension); this visit also 8 
allowed for adjustment of back-ground diuretic or other non-essential therapies. Dose reduction to 5 9 
mg of dapagliflozin or matching placebo (or discontinuation of study drug) was to be considered in 10 
case of an acute unexpected decline in eGFR, volume depletion or hypotension (or to avoid these 11 
conditions); however, dose up-titration (or re-initiation) was encouraged thereafter in all cases, where 12 
possible. 13 
 14 
Study outcomes 15 
The primary outcome was the composite of an episode of worsening heart failure (HF hospitalization 16 
or urgent HF visit) or cardiovascular (CV) death, whichever occurred first. Secondary endpoints were 17 
the occurrence of HF hospitalization or CV death; HF hospitalizations (first and recurrent) and 18 
cardiovascular deaths; change from baseline to 8 months in the total symptom score of the Kansas 19 
City Cardiomyopathy Questionnaire (KCCQ) [11]; the incidence of a composite worsening renal 20 
function outcome, consisting of (a) ≥50% sustained decline in eGFR, (b) end-stage renal disease 21 
(defined as sustained eGFR<15 mL/min/1.73 m2, chronic dialysis treatment or renal transplantation) 22 
or (c) renal death; and death from any cause. Prespecified safety analyses included serious adverse 23 
events, adverse events leading to discontinuation of trial treatment, adverse events of interest (i.e., 24 
10 
 
volume depletion, renal events, major hypoglycemic events, bone fractures, diabetic ketoacidosis, 1 
amputation) and any diagnosis of Fournier’s gangrene, as well as laboratory findings of note. 2 
 3 
Statistical analysis 4 
In the present study, patients were divided into four age categories: (i) <55 years, (ii) 55–64 years, (iii) 5 
65–74 years, and (iv) ≥75 years. Baseline characteristics were summarized as means and standard 6 
deviations, medians, and interquartile ranges, or percentages. Time-to-event data were evaluated 7 
with the use of Kaplan-Meier estimates and Cox proportional-hazards models, stratified according to 8 
diabetes status, with a history of HF hospitalization and treatment-group assignment as fixed-effect 9 
factors. We used Cox models to calculate hazard ratios, 95% confidence intervals, and two-sided P 10 
values and used a semiparametric proportional-rates model to calculate total (including recurrent) 11 
events [12]. We analyzed the change in total symptom score on the KCCQ from baseline to 8 months 12 
in surviving patients. Safety analyses were performed in patients who had undergone randomization 13 
and received at least one dose of dapagliflozin or placebo (a total of 8 patients were excluded). The 14 
effect of dapagliflozin compared with placebo on each outcome was also examined across the 15 
spectrum of age, in a Cox regression model in which age was modelled as a continuous variable. A 16 
fractional polynomial was constructed of age and entered into the model as an interaction term with 17 
treatment [13]. The results of the interaction were displayed graphically using the “mfpi” command in 18 
STATA [14]. The interaction between age and treatment on the occurrence of the pre-specified safety 19 
outcomes was tested in a logistic regression model with an interaction term between age and 20 
treatment. The effect of differences in baseline characteristics was examined by adjustment of the 21 
model in sensitivity analysis (Table S1 and Figure S1, supplementary appendix). Additional exploratory 22 
analyses were conducted in very elderly patients i.e. those aged 75-80 and 80-85 years; we have 23 
provided these two categories, along with the categories ages ≥80 and ≥85 years. All analyses were 24 
11 
 
conducted using STATA version 15.1 (College Station, TX, USA). A P-value of 0.05 was considered 1 
statistically significant.  2 
12 
 
RESULTS 1 
Overall, 4744 patients aged between 22 and 94 years were randomized. The mean age was 66.3 2 
(standard deviation 10.9) years.  The number and proportion of patients in the different age categories 3 
analysed are shown in Table 1. There were 636 patients <55 years (13.4%), median age 49 (44-52) 4 
years; 1242 participants between 55 and 64 years (26.2%), median age 60 (58-62) years; 1717 patients 5 
aged 65 to 74 years (36.2%), median age 69 (67-72) years; and 1149 individuals ≥75 years (24.2%), 6 
median age 79 (76-82) years.  7 
 8 
Patient characteristics 9 
Compared to younger participants, older patients were more often women, white, and enrolled in 10 
Western Europe and North America. Older patients also had a higher average systolic blood pressure, 11 
serum creatinine, and natriuretic peptide levels, as well as a higher average ejection fraction (Table 12 
1). Older patients were also more likely than younger patients to be in NYHA functional class III/IV, 13 
than in class II, and to have hypertension, coronary artery disease and atrial fibrillation. Median 14 
baseline KCCQ total symptom score (KCCQ-TSS) was similar (mean 76/75) in the <55 years and 55–64 15 
years groups, but higher (mean 79) among patients in the two older age categories (65–74 and the 16 
≥75 years) i.e. older patients had less severe symptoms. With respect to background heart failure 17 
medications, patients in the older groups were less frequently treated with beta-blockers, 18 
mineralocorticoid receptor antagonists (MRAs), diuretics, and digitalis than younger patients. Baseline 19 
use of angiotensin receptor neprilysin inhibitors (ARNI) was generally low but similar across age 20 
groups. The proportion of patients treated with cardiac resynchronization therapy increased with age, 21 
but patients aged ≥75 years were less likely to receive an implantable cardioverter-defibrillator (ICD) 22 
compared to those aged 55-64 or 65-74 years. Use of oral anticoagulant therapy increased with age 23 
while antiplatelet use was higher in patients aged 55-64 years. 24 
13 
 
 1 
Primary composite outcome 2 
The unadjusted incidence of the primary composite outcome of a first episode of worsening HF or CV 3 
death, according to age is shown in Table 2 and Figure 1. The incidence of this endpoint in the placebo 4 
group was relatively similar in the age categories 55-64 and 65–74 years but was higher in those aged 5 
75 years or older and lower in those aged <55 years. The hazard ratio (HR) for the effect of dapagliflozin 6 
compared with placebo on the primary outcome, was consistent across the spectrum of age (Table 2 7 
and Figure 2A), with a P-value for interaction of 0.76. 8 
Applying the overall relative risk reduction (26%) to the placebo group event rate in those aged ≥75 9 
years gave an absolute risk reduction of 47 fewer patients experiencing a primary outcome per 1000 10 
person years of follow-up. The equivalent absolute risk reduction in patients aged <55 years was 11 
estimated as 35 fewer patients per 1000 person years of follow-up. 12 
 13 
Cardiovascular death 14 
As shown in Table 2 and Figure 2B, the rate of CV death in the placebo group did not vary greatly 15 
across age categories. The effect of dapagliflozin compared with placebo was consistent across the 16 
spectrum of age (Table 2 and Figure 2B). The P-value for interaction was not significant (P-value for 17 
interaction = 0.97). 18 
 19 
Worsening heart failure events 20 
By contrast, there was more evidence of an increasing rate of worsening HF events, in the placebo 21 
group, with increasing age (Table 2 and Figure 2C). The effect of dapagliflozin compared with placebo 22 
was consistent across all age groups, including in patients ≥75 years (Table 2 and Figure 2C). Applying 23 
14 
 
the overall relative risk reduction (30%) to placebo group event rate in those aged ≥75 years, gave an 1 
absolute risk reduction of 36 per 1000 person years of follow-up. The equivalent absolute risk 2 
reduction in patients aged <55 years was estimated as 23 per 1000 person years of follow-up. 3 
 4 
All-cause mortality 5 
As shown in Table 2 and Figure 2D, the rate of death from any cause increased steadily across age 6 
categories, with the highest rate in patients ≥75 years. The effect of dapagliflozin compared with 7 
placebo was consistent across the spectrum of age (Table 2 and Figure 2D; P-value for interaction 8 
0.93). Applying the overall relative risk reduction (17%) to placebo group event rate in those aged 9 
≥75 years, gave an absolute risk reduction of 19 fewer deaths per 1000 person years of follow-up. 10 
The equivalent absolute risk reduction in patients aged <55 years was estimated as 13 fewer deaths 11 
per 1000 person years. 12 
 13 
Composite of recurrent heart failure hospitalization and cardiovascular death 14 
As for the other endpoints, we observed a consistent effect of dapagliflozin on the occurrence of first 15 
and recurrent HF hospitalization and CV death across age categories (Table 2) (P-value for interaction 16 
=0.72). 17 
 18 
Effect of dapagliflozin compared to placebo with age as a continuous variable 19 
Figure 3 provides an alternative illustration of the effects of dapagliflozin compared with placebo, for 20 
the four outcomes described above, using fractional polynomial analysis. Each panel shows a 21 
continuous HR (with 95% CI) for dapagliflozin, compared with placebo, across the spectrum of age 22 
(age shown as a continuous variable on the X-axis). The polynomial allows for the possibility of a 23 
15 
 
non-linear effect of treatment by age to be modeled. As in the categorical analysis, the effect of 1 
dapagliflozin, compared with placebo, was consistent across the entire spectrum of age. The 2 
continuous HR was linear (Figure 3). Similar findings were also observed after adjusting for 3 
differences in baseline characteristics (Figure S1, supplementary appendix). 4 
 5 
Change in Kansas City Cardiomyopathy Questionnaire at 8 months 6 
As shown in Table 2, patients treated with dapagliflozin, overall, had a greater increase 7 
(improvement) in the KCCQ-TSS between baseline and 8 months and this benefit of dapagliflozin was 8 
consistent across age categories (P-value for interaction =0.65).  9 
The proportion of patients with an improvement of KCCQ-TSS of ≥5 points was greater in patients 10 
treated with dapagliflozin, compared to patients treated with placebo. Conversely, the proportion of 11 
patients with a decrease in KCCQ-TSS of ≥5 points (i.e. a clinically meaningful deterioration) was 12 
smaller in those treated with dapagliflozin. The benefit of dapagliflozin over placebo in both 13 
improving KCCQ-TSS, and in preventing deterioration, was consistent across age groups (P-value for 14 
each interaction=0.96). The numbers needed to treat (NNT) for one patient to have a clinically 15 
meaningful improvement in symptoms over 8 months was 14 overall, ranging from 10 to 29 across 16 
age groups; the NNT for 8 months to prevent one patient having a clinically important deterioration 17 
was 13 overall, ranging from 9 to 22, across age groups. 18 
Additional exploratory analyses were carried out to evaluate safety in very elderly patients; these are 19 
provided in the Supplementary Appendix (Tables S2 and Table S3). 20 
 21 
Pre-specified safety assessments 22 
Table 3 shows the occurrence of the pre-specified adverse events of interest, according to age 23 
category. The proportion of patients stopping study-drug for any reason increased with increasing 24 
16 
 
age in the placebo group. However, the rate of discontinuation was similar between dapagliflozin 1 
and placebo, with no interaction between age category and the effect of treatment (P-value for 2 
interaction =0.38). The incidence of any adverse event leading to permanent treatment 3 
discontinuation increased with increasing age in the placebo group, with the highest incidence in 4 
patients aged ≥75 years (5.9% compared with 3.4% in the <55 years group). Discontinuation of study 5 
drug due to adverse events was similar in the two treatment arms (dapagliflozin and placebo) in 6 
each age category. For example, in the ≥75 years group, discontinuation for an adverse event 7 
occurred in 5.8% of patients randomized to dapagliflozin, compared with 5.9% randomized to 8 
placebo.  9 
A similar age-related pattern was observed for adverse events, and serious adverse events, overall. 10 
The most common of the pre-specified safety outcomes of interest were adverse events related to 11 
volume depletion and renal adverse events. Volume depletion adverse events were reported in 12 
10.1% of the placebo group aged ≥75 years and in 10.5% in the dapagliflozin group. Renal adverse 13 
events were reported in 6.8% of the dapagliflozin and 10.6% of the placebo group aged ≥75 years.  14 
Serious adverse events related to volume depletion occurred, overall, in 29 patients (1.2%) in the 15 
dapagliflozin group and 40 patients (1.7%) in the placebo group, without any interaction between 16 
age categories and treatment effect (P for interaction =0.15). Serious renal adverse events occurred 17 
in 38 patients (1.6%) in the dapagliflozin group and 65 patients (2.7%) in the placebo group, with a 18 
signification interaction between age category and the effect of dapagliflozin (P for interaction 19 
=0.002). Specifically, in patients ≥75 years, the incidence of serious renal adverse events was 0.5% in 20 
the dapagliflozin group, compared with 5.4% in the placebo group, although it should be noted that 21 
the number of these events was small. The mean change in serum creatinine with dapagliflozin at 8 22 
months was minimal across each age category (P-value for interaction =0.78) and relatively few 23 
patients in any age group (and either treatment group) experienced a doubling of serum creatinine.  24 
17 
 
The mean change in systolic blood pressure with dapagliflozin at 8 months was small and similar in 1 
each age category (P-value for interaction =0.97). 2 
Additional exploratory analyses were carried out to evaluate safety in very elderly patients; these are 3 
provided in the Supplementary Appendix (Tables S2 and Table S3). 4 
  5 
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 DISCUSSION 1 
Patients enrolled in the DAPA-HF trial were older than in most previous HFrEF trials [15–17], and had 2 
a mean age close to that reported in contemporary registries [18]. Dapagliflozin reduced worsening 3 
heart failure events and death across all age categories, with larger absolute benefits in older 4 
patients. Dapagliflozin also improved symptoms in each age group, with no heterogeneity of 5 
treatment effect. Dapagliflozin was well tolerated, with no significant difference between 6 
dapagliflozin and placebo in any age group. Indeed, serious renal adverse events were less frequent 7 
with dapagliflozin in the oldest age category. Therefore, the benefit/risk profile of dapagliflozin was 8 
as favorable in older, compared with younger patients. 9 
We found, predictably, that baseline characteristic differed substantially across age categories. As 10 
observed in previous trials [15,19], older patients were more often women, hypertensive and had a 11 
higher prevalence of atrial fibrillation and impaired renal function, compared with younger 12 
participants. Older patients had higher NT-proBNP levels than younger patients. As reported in the 13 
PARADIGM-HF trial [20], non-white individuals and patients from the Asia-Pacific region were 14 
younger than white participants. In DAPA-HF overall, a larger proportion of patients were receiving 15 
guideline-recommended life-saving medications (i.e. mineralocorticoid receptor antagonists and 16 
beta-blockers), compared with previous trials, and this was also true for patients in the oldest age 17 
group.  18 
We observed a higher rate of events as age increased, although this gradient was clearer for 19 
worsening HF events than for CV death. The high rate of use of disease-modifying drugs at baseline 20 
may have contributed to the attenuated age-related gradient in CV death, which, as in PARADIGM-21 
HF was less steep than in historical trials [21].  22 
As clearly shown in Figures 2 and 3, the benefit of dapagliflozin on each of the four 23 
mortality/hospitalization outcomes examined was consistent across the whole age range studied.  24 
Because older patients were at higher absolute risk, the absolute benefit of dapagliflozin was 25 
19 
 
greatest in the most elderly participants (≥75 years), with 47 few patients in this age group, per 1000 1 
treated, experiencing a primary endpoint over the duration of the trial. In addition to their higher 2 
baseline risk, older patients received slightly less conventional disease-modifying therapy which may 3 
also have amplified the benefit of dapagliflozin.  Whatever the precise explanation, the benefits 4 
observed emphasize the importance of overcoming the therapeutic nihilism that often characterizes 5 
the management of older patients with many diseases, and above all older women who comprised 6 
28% of the oldest group in the present analysis [7]. Our data clearly show that dapagliflozin has 7 
substantial, clinically important, benefits in older as well as younger patients.  8 
For older patients, improvement, or at least prevention of deterioration, in symptoms may be as 9 
important as extending life and it is also important to note that the overall improvement in KCCQ-10 
TSS was as large in older individuals as it was in younger patients. Indeed, the NNTs to achieve a 11 
clinically important improvement, or to prevent a significant deterioration, in symptoms were small 12 
and as favourable in older patients as younger patients. 13 
Our analyses of safety and tolerability were also reassuring.  Although adverse events and study drug 14 
discontinuation increased with age (in the placebo group), neither was common and more 15 
relevantly, they did not differ by treatment group. Importantly, renal dysfunction which can be a 16 
particular problem in older individuals with HFrEF, was not more common with dapagliflozin and 17 
serious renal adverse events were actually less common in the dapagliflozin group. It is difficult to 18 
make direct comparisons of safety outcomes with prior SGLT2 inhibitor trials as the patients included 19 
in DAPA-HF were at much higher cardiovascular risk, had more underlying renal dysfunction and 20 
were receiving quite different background therapy, particularly use of renin-angiotensin system 21 
blockers and diuretics. Collection of safety information was also different, with targeted 22 
identification of specific adverse effects, especially those related to concerns in patients with heart 23 
failure (volume depletion and renal dysfunction). 24 
20 
 
As with other similar studies, there are some obvious limitations. This is a post hoc analysis, and the 1 
age categories chosen were arbitrary (although commonly used in similar studies). The number of 2 
African American patients was relatively small, although similar to other global HFrEF trials [15,22]. 3 
As in other trials, the prespecified inclusion and exclusion criteria will have reduced enrolment of 4 
very high-risk patients. These limitations could affect the generalizability of our results.   5 
21 
 
CONCLUSIONS 1 
Dapagliflozin reduced the risk of death and worsening heart failure, and improved symptoms, across 2 
the broad spectrum of age studied in DAPA-HF. There was no significant imbalance in tolerability or 3 
safety events between dapagliflozin and placebo, even in elderly individuals.  4 
22 
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TABLES AND FIGURES LEGENDS 
TABLE 1. Baseline Characteristics According to Age Categories. *Glycated hemoglobin values are listed only 
for the patients with diabetes. †the numbers are relative to patients with type II diabetes history at baseline. 
ACE denotes Angiotensin Converting Enzyme, ARB Angiotensin Receptor Blocker, ARNI Angiotensin Receptor 
Neprilysin Inhibitor, BMI Body Mass Index, CABG Coronary Artery Bypass Grafting, CRT-D Cardiac 
Resynchronization Therapy – Defibrillator, CRT-P Cardiac Resynchronization Therapy - Pacemaker, DPP-4 
Dipeptidyl peptidase-4, GFR Glomerular Filtration Rate, GLP-1 Glucagon-like Peptide 1, ICD Implantable 
Cardioverter-Defibrillator, MI Myocardial Infarction, NYHA New York Heart Association, KCCQ Kansas City 
Cardiomyopathy Questionnaire, PCI Percutaneous Coronary Intervention. 
TABLE 2. Clinical Outcomes According to Age Categories. CV death denotes cardiovascular death, HF heart 
failure. *P value are for interaction between baseline age categories and treatment effect. 
TABLE 3. Occurrence of Adverse Events According to Age Categories (patients receiving at least one dose 
of study drug). *P value is for interaction between age categories and treatment effect on the occurrence of 
adverse events. †P value not provided because of few events. AE denotes Adverse Event, SBP Systolic Blood 
Pressure. 
 
FIGURE 1. Cumulative Incidence of the Primary Outcome according to Age Categories. 
FIGURE 2. Effect of Dapagliflozin according to Age Categories. Panel A shows Occurrence of Primary 
Outcome, panel B shows Cardiovascular Death, panel C shows HF Hospitalization/Urgent Visit and panel D 
shows All-Cause Death. P values are for interaction between baseline age categories and treatment effect. 
CV Death denotes Cardiovascular Death, HF heart failure. P value are for interaction between baseline age 
categories and treatment effect. CV Death denotes Cardiovascular Death, HF heart failure.  
FIGURE 3. Effect of Dapagliflozin on the Occurrence of Outcomes by Age. CV Death denotes Cardiovascular 
Death, HF heart failure.  
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TABLE 1 – Baseline Characteristics According to Age Categories. 
Variable <55 years 
(n=636) 
55–64 years 
(n=1242) 
65-74 years 
(n=1717) 
≥75 years 
(n=1149) P for trend 
Age - years 47.1 (6.3) 59.9 (2.8) 69.4 (2.8) 79.4 (3.6)  
Female - no. (%) 120 (18.9) 265 (21.3) 403 (23.5) 321 (27.9) <0.001 
Race - no. (%)     <0.001 
White 327 (51.4) 844 (68.0) 1280 (74.5) 882 (76.8)  
Black or African American 50 (7.9) 77 (6.2) 65 (3.8) 34 (3.0)  
Asian 243 (38.2) 297 (23.9) 352 (20.5) 224 (19.5)  
Other 16 (2.5) 24 (1.9) 20 (1.2) 9 (0.8)  
Region – no. (%)     <0.001 
North America 83 (13.1) 157 (12.6) 245 (14.3) 192 (16.7)  
South America 123 (19.3) 262 (21.1) 278 (16.2) 154 (13.4)  
Europe 188 (29.6) 530 (42.7) 852 (49.6) 584 (50.8)  
Asia/Pacific 242 (38.1) 293 (23.6) 342 (19.9) 219 (19.1)  
Systolic blood pressure - mmHg 117.7 ± 17.1 121.0 ± 16.1 122.9 ± 15.8 123.4 ± 16.5 <0.001 
Diastolic blood pressure - mmHg 75.0 ± 11.2 74.9 ± 10.4 73.4 ± 10.0 71.4 ± 10.5 <0.001 
Heart rate - bpm 74.5 ± 12.2 72.2 ± 12.1 70.8 ± 11.0 70.3 ± 11.7 <0.001 
BMI - kg/m2 29.2 ± 7.4 28.9 ± 6.0 28.2 ± 5.6 26.7 ± 5.1 <0.001 
Creatinine - mg/dl 1.08 ± 0.31 1.14 ± 0.36 1.21 ± 0.34 1.24 ± 0.33 <0.001 
Creatinine - μmol/L 95.9 ± 27.7 100.9 ± 31.7 106.8 ± 30.0 109.4 ± 29.6 <0.001 
Glycated Hemoglobin* - % 7.8 (1.8) 7.7 (1.8) 7.3 (1.4) 7.0 (1.1) <0.001 
Estimated GFR - mL/min/1.73m2 83.0 ± 20.5 71.5 ± 18.3 62.0 ± 16.5 55.6 ± 15.2 <0.001 
Median NTproBNP - pg/ml (IQR)  1107 (648, 
2241) 
1332 (813, 
2394) 
1453 (881, 
2644) 
1737 (1068, 
3161) <0.001 
Heart failure etiology - no. (%)     <0.001 
Ischemic etiology 258 (40.6) 660 (53.1) 1053 (61.3) 703 (61.2)  
Non-ischemic etiology 316 (49.7) 478 (38.5) 536 (31.2) 357 (31.1)  
Unknown 62 (9.7) 104 (8.4) 128 (7.5) 89 (7.7)  
Ejection fraction - % 29.2 ± 7.2 30.5 ± 6.9 31.3 ± 6.6 32.3 ± 6.5 <0.001 
NYHA Class – no. (%)     0.018 
II 442 (69.5) 860 (69.2) 1153 (67.2) 748 (65.1)  
III 184 (28.9) 368 (29.6) 553 (32.2) 393 (34.2)  
IV 10 (1.6) 14 (1.1) 11 (0.6) 8 (0.7)  
KCCQ total symptoms score at 
baseline (IQR) 76 (52, 92) 75 (57, 92) 79 (60, 93) 79 (60, 92) <0.001 
Medical history – no (%) 
Hypertension  343 (53.9) 871 (70.1) 1357 (79.0) 951 (82.8) <0.001 
Type 2 Diabetes  215 (33.8) 564 (45.4) 758 (44.1) 446 (38.8) 0.50 
Atrial Fibrillation  118 (18.6) 401 (32.3) 718 (41.8) 581 (50.6) <0.001 
Hospitalization for Heart Failure  317 (49.8) 596 (48.0) 824 (48.0) 514 (44.7) 0.042 
Prior MI 198 (31.1) 535 (43.1) 833 (48.5) 526 (45.8) <0.001 
Prior PCI 139 (21.9) 410 (33.0) 655 (38.1) 420 (36.6) <0.001 
Prior CABG 42 (6.6) 173 (13.9) 358 (20.9) 226 (19.7) <0.001 
Treatment – no (%) 
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ACE inhibitor  393 (61.8) 720 (58.0) 958 (55.8) 590 (51.3) <0.001 
ARB 143 (22.5) 323 (26.0) 477 (27.8%) 364 (31.7) <0.001 
ARNI  70 (11.0) 141 (11.4) 181 (10.5) 116 (10.1) 0.37 
Diuretic  611 (96.1) 1183 (95.2) 1598 (93.1) 1041 (90.6) <0.001 
Digitalis 146 (23.0) 245 (19.7) 313 (18.2) 183 (15.9) <0.001 
Beta-blocker  624 (98.1) 1211 (97.5) 1642 (95.6) 1081 (94.1) <0.001 
Mineralocorticoid antagonist  527 (82.9) 939 (75.6) 1192 (69.4) 712 (62.0) <0.001 
Oral anticoagulant  162 (25.5) 465 (37.4) 769 (44.8) 573 (49.9) <0.001 
Antiplatelet 324 (50.9) 711 (57.2) 961 (56.0) 596 (51.9) 0.61 
Statin 342 (53.8) 836 (67.3) 1222 (71.2) 776 (67.5) <0.001 
ICD 116 (18.2) 265 (21.3) 388 (22.6) 184 (16.0) 0.15 
CRT-D 19 (3.0) 68 (5.5) 121 (7.0) 81 (7.0) <0.001 
ICD or CRT-D 135 (21.2) 333 (26.8) 509 (29.6) 265 (23.1) 0.51 
CRT-P/CRT-D 23 (3.6) 83 (6.7) 142 (8.3) 106 (9.2) <0.001 
Diabetes treatment – no (%)† 
 <55 years 
(n=215) 
55–64 years 
(n=564) 
65-74 years 
(n=758) 
≥75 years 
(n=446)  
Biguanide 117 (54.4) 315 (55.9) 392 (51.7) 192 (43.0) <0.001 
Sulfonylurea 50 (23.3) 131 (23.2) 168 (22.2) 89 (20.0) 0.22 
DPP-4 inhibitor 21 (9.8) 71 (12.6) 127 (16.8) 91 (20.4) <0.001 
GLP-1 receptor agonist 5 (2.3) 1 (0.2) 12 (1.6) 3 (0.7) 0.61 
Insulin 57 (26.5) 161 (28.5) 228 (30.1) 94 (21.1) 0.085 
*Glycated hemoglobin values are listed only for the patients with diabetes. †the numbers are relative to patients with type II 
diabetes history at baseline. ACE denotes Angiotensin Converting Enzyme, ARB Angiotensin Receptor Blocker, ARNI Angiotensin 
Receptor Neprilysin Inhibitor, BMI Body Mass Index, CABG Coronary Artery Bypass Grafting, CRT-D Cardiac Resynchronization 
Therapy – Defibrillator, CRT-P Cardiac Resynchronization Therapy - Pacemaker, DPP-4 Dipeptidyl peptidase-4, GFR Glomerular 
Filtration Rate, GLP-1 Glucagon-like Peptide 1, ICD Implantable Cardioverter-Defibrillator, MI Myocardial Infarction, NYHA New York 
Heart Association, KCCQ Kansas City Cardiomyopathy Questionnaire, PCI Percutaneous Coronary Intervention.
28 
 
TABLE 2. Clinical Outcomes According to Age Categories. 
 <55 years (n=636) 55–64 years (n=1242) 65-74 years (n=1717) ≥75 years (n=1149) P value for interaction* 
Outcome Placebo 
(n=296) 
Dapagliflozin 
(n=340) 
Placebo 
(n=630) 
Dapagliflozin 
(n=612) 
Placebo 
(n=887) 
Dapagliflozin 
(n=830) 
Placebo 
(n=558) 
Dapagliflozin 
(n=591)  
CV death or HF hospitalization/urgent HF visit 0.76 
No. (%) 53 (17.9) 52 (15.3) 131 (20.8) 96 (15.7) 184 (20.7) 135 (16.3) 134 (24.0) 103 (17.4) 
 Rate (95% CI) 13.6 (10.4-17.9) 
11.8 (9.0-
15.5) 
15.7 (13.2-
18.7) 
11.4 (9.3-
13.9) 
15.1 (13.1-
17.5) 
11.4 (9.6-
13.5) 
18.0 (15.2-
21.4) 
12.6 (10.4-
15.3) 
HR 0.87 (0.60-1.28), P=0.49 0.71 (0.55-0.93), P=0.012 0.76 (0.61-0.95), P=0.015 0.68 (0.53-0.88), P=0.003 
CV death 0.97 
No. (%) 29 (9.8) 28 (8.2) 70 (11.1) 60 (9.8) 107 (12.1) 79 (9.5) 67 (12.0) 60 (10.2) 
 Rate (95% CI) 7.0 (4.9-10.1) 6.0 (4.1-8.6) 7.8 (6.2-9.9) 6.8 (5.3-8.8) 8.3 (6.9-10.0) 6.4 (5.1-8.0) 8.3 (6.5-10.6) 7.0 (5.5-9.1) 
HR 0.85 (0.51-1.43), P=0.54 0.87 (0.62-1.23), P=0.45 0.78 (0.58-1.04), P=0.089 0.83 (0.58-1.17), P=0.29 
HF hospitalization/urgent HF visit 0.18 
No. (%) 29 (9.8) 34 (10.0) 90 (14.3) 52 (8.5) 117 (13.2) 86 (10.4) 90 (16.1) 65 (11.0) 
 Rate (95% CI) 7.5 (5.2-10.7) 7.7 (5.5-10.8) 10.8 (8.8-13.3) 6.2 (4.7-8.1) 9.6 (8.0-11.5) 7.3 (5.9-9.0) 
12.1 (9.9-
14.9) 8.0 (6.2-10.1) 
HR 1.05 (0.64-1.72), P=0.85 0.56 (0.40-0.78), P=0.001 0.76 (0.58-1.01), P=0.056 0.64 (0.47-0.88), P=0.006 
All-cause death 0.93 
No. (%) 31 (10.5) 29 (8.5) 80 (12.7) 72 (11.8) 129 (14.5) 99 (11.9) 89 (16.0) 76 (12.9) 
 Rate (95% CI) 7.5 (5.3-10.7) 6.2 (4.3-8.9) 8.9 (7.2-11.1) 8.2 (6.5-10.3) 10.0 (8.4-11.9) 8.0 (6.6-9.7) 
11.0 (9.0-
13.6) 8.9 (7.1-11.1) 
HR 0.81 (0.49-1.35), P=0.43 0.91 (0.66-1.25), P=0.57 0.80 (0.62-1.05), P=0.10 0.79 (0.58-1.08), P=0.14 
CV death/HF hospitalization recurrent events 0.72 
No. of events  81 80 198 134 268 202 195 151  
HR 0.89 (0.57-1.41), P=0.63 0.68 (0.51-0.91), P=0.010 0.80 (0.62-1.02), P= 0.076 0.70 (0.53-0.94), P=0.016  
KCCQ  
Change in KCCQ 
TSS score at 8 
months 
5.1 (20.4) 6.7 (19.8) 4.7 (19.0) 6.8 (20.6) 3.0 (19.1) 6.3 (17.2) 1.2 (19.0) 4.9 (17.8) 0.65 
Patients with ≥5 
points 
improvement in 
52.9 56.4 53.3 59.5 50.5 60.4 48.0 55.2 0.96 
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KCCQ at 8 months 
- % 
Patients with ≤5 
points decrease in 
KCCQ at 8 months 
- % 
30.2 25.7 31.3 25.7 34.2 23.3 33.9 27.6 0.96 
CV death denotes cardiovascular death, HF heart failure. *P value are for interaction between baseline age categories and treatment effect. 
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TABLE 3. Occurrence of Adverse Events According to Age Categories (patients receiving at least one dose of study drug). 
 <55 years (n=634) 55–64 years (n=1240) 65-74 years (n=1716) ≥75 years (n=1146) P value for interaction* 
Adverse event Placebo 
(n=295) 
Dapagliflozin 
(n=339) 
Placebo 
(n=630) 
Dapagliflozin 
(n=610) 
Placebo 
(n=886) 
Dapagliflozin 
(n=830) 
Placebo 
(n=557) 
Dapagliflozin 
(n=589)  
Volume depletion 14 (4.7) 23 (6.8) 35 (5.6) 36 (5.9) 57 (6.4) 57 (6.9) 56 (10.1) 62 (10.5) 0.86 
Serious volume depletion 3 (1.0) 1 (0.3) 12 (1.9) 5 (0.8) 11 (1.2) 15 (1.8) 14 (2.5) 8 (1.4) 0.15 
Renal adverse event 11 (3.7) 14 (4.1) 33 (5.2) 48 (7.9) 67 (7.6) 51 (6.1) 59 (10.6) 40 (6.8) 0.031 
Serious renal adverse 
event 4 (1.4) 3 (0.9) 9 (1.4) 13 (2.1) 22 (2.5) 19 (2.3) 30 (5.4) 3 (0.5) 0.002 
Fracture 0 (0.0) 1 (0.3) 11 (1.7) 11 (1.8) 24 (2.7) 13 (1.6) 15 (2.7) 24 (4.1) † 
Amputation 0 (0.0) 2 (0.6) 2 (0.3) 4 (0.7) 5 (0.6) 6 (0.7) 5 (0.9) 1 (0.2) † 
Major hypoglycemia 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.1) 2 (0.2) 3 (0.5) 1 (0.2) † 
Diabetic ketoacidosis 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.3) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) † 
AE leading to permanent 
treatment discontinuation 10 (3.4) 10 (2.9) 23 (3.7) 25 (4.1) 50 (5.6) 42 (5.1) 33 (5.9) 34 (5.8) 0.93 
AE leading to temporary 
treatment discontinuation 34 (11.5) 29 (8.6) 75 (11.9) 73 (12.0) 133 (15.0) 112 (13.5) 107 (19.2) 70 (11.9) 0.09 
AE leading to treatment 
dose reduction 4 (1.4) 9 (2.7) 7 (1.1) 7 (1.1) 8 (0.9) 13 (1.6) 6 (1.1) 14 (2.4) 0.75 
Any serious adverse event 
(including death) 101 (34.2) 111 (32.7) 252 (40.0) 213 (34.9) 366 (41.3) 319 (38.4) 275 (49.4) 252 (42.8) 0.61 
Discontinuation of study-
drug for any reasons 22 (7.5) 37 (10.9) 57 (9.0) 50 (8.2) 104 (11.7) 90 (10.8) 75 (13.5) 72 (12.2) 0.38 
Doubling of serum 
creatinine at 8 months 30 (10.2) 43 (12.7) 79 (12.5) 57 (9.3) 98 (11.1) 77 (9.3) 68 (12.2) 61 (10.4) 0.31 
Change in creatinine with 
dapagliflozin (mg/dL) 0.04 (-0.01 to 0.09), P=0.096 -0.01 (-0.04 to 0.02), P=0.49 0.03 (0.01 to 0.06), P=0.017 0.03 (-0.01 to 0.06), P=0.10 0.78 
Change in SBP with 
dapagliflozin (mmHg) -1.97 (-4.29 to 0.35), P=0.095 -0.36 (-2.06 to 1.34), P=0.68 -1.97 (-3.40 to -0.54), P=0.007 -1.42 (-3.26 to -0.42), P=0.13 0.97 
*P value is for interaction between age categories and treatment effect on the occurrence of adverse events. †P value not provided because of few events. AE denotes Adverse Event, SBP systolic 
blood pressure. 
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FIGURE 1. Cumulative Incidence of the Primary Outcome according to Age Categories. 
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FIGURE 2. Effect of Dapagliflozin according to Age Categories. Panel A shows Occurrence of Primary Outcome, panel B shows Cardiovascular Death, panel C 
shows HF Hospitalization/Urgent Visit and panel D shows All-Cause Death. 
 
P value are for interaction between baseline age categories and treatment effect. CV Death denotes Cardiovascular Death, HF heart failure.  
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FIGURE 3. Effect of Dapagliflozin on the Occurrence of Outcomes by Age. 
 
CV Death denotes Cardiovascular Death, HF heart failure. 
 
 
